Biogen (BIIB) Other Accumulated Expenses (2009 - 2026)

Biogen (BIIB) has reported Other Accumulated Expenses for 18 consecutive years, with $2.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 0.64% year-over-year to $2.5 billion; the TTM figure through Mar 2026 stood at $2.5 billion (up 0.64% YoY), while the FY2025 annual figure was $2.8 billion, changed 0.18% from the prior year.
• Other Accumulated Expenses came in at $2.5 billion for Q1 2026 at Biogen, down from $2.8 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.8 billion in Q3 2023, with the low at $2.2 billion in Q1 2022.
• Average Other Accumulated Expenses over 5 years is $2.7 billion, with a median of $2.6 billion recorded in 2023.
• Across the five-year window, Other Accumulated Expenses grew 29.61% in 2022 and decreased 28.22% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $2.5 billion in 2022, then gained by 4.05% to $2.6 billion in 2023, then rose by 7.02% to $2.8 billion in 2024, then slipped by 0.18% to $2.8 billion in 2025, then fell by 9.13% to $2.5 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.5 billion, $2.8 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.